A paradigm shift in the treatment of advanced non-small cell lung cancer

American Journal of the Medical Sciences

Volumn 344, Issue 2, 2012, Pages 147-150

  Varughese, Shibu ^a   Jahangir, K Saad ^a   Simpson, Catherine E ^b   Boulmay, Brian C ^a  

^a Section of Hematology Oncology   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemotherapy; Lung cancer; Maintenance chemotherapy; NSCLC; Platinum based

Indexed keywords

CARBOPLATIN; PACLITAXEL; THYROID TRANSCRIPTION FACTOR 1;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; BRAIN METASTASIS; BREATHING; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOHISTOCHEMISTRY; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; PERIPHERAL NEUROPATHY; REVIEW; SMOKING; TUMOR BIOPSY;

EID: 84864351774     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e318246e1b8     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, . CA Cancer J Clin2008 2008;58:71-96.
2. Youlden DR, Cramb SM, Baade PD. The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008;3:819-831.
3. American Cancer Society. Cancer Facts and Figures 2010. Atlanta (GA): American Cancer Society; 2010.
4. Beasley MB, Brambilla E, Travis WD. The 2004 World Health Organization classification of lung tumors. Semin Roentgenol 2005;40:90-97.
5. Wynder EL, Muscat JE. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect 1995;103(suppl 8): 143-8. (Pubitemid 26040890)
6. National Cancer Institute. Surveillance Epidemiology and End Results (SEER Database). http://seer.cancer.gov/faststats. Accessed January 3, 2011.
7. Spiroa SG, Rudd RM, Souhami RL, et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004;59:828-836. (Pubitemid 39389621)
8. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98. (Pubitemid 34438899)
9. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): An open-label randomised phase III trial. Lancet 2009;373:1525-1531.
10. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550. (Pubitemid 44917502)
11. Smith IE, O'Brien ME, Talbot DC, et al. Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 2001;19:1336-1343. (Pubitemid 32202538)
12. Westeel V, Quoix E, Moro-Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499-506. (Pubitemid 40590431)
13. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl JMed 2005;353:123-132. (Pubitemid 41058344)
14. Miller VA, O'Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer. J Clin Oncol 2009;27(suppl LBA8002):407s.
15. Kabbinavar FF, Miller VA, Johnson BE. Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung cancer (NSCLC). J Clin Oncol 2010;28:15s, (suppl; abstr 7526).
16. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11: 521-9.
17. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: A randomised, double-blind, phase 3 study. Lancet 2009;374:1432-1440.
18. Paz-Ares LG, De Marinis F, Dediu M, et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29:(suppl; abstr CRA7510).
19. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591-598.
20. Bastos DA, Calabrich A, Katz A. Pemetrexed-induced fluid retention. J Thorac Oncol 2010;5:752.